Pharmagreen Biotech, Inc. Unveils High-Revenue Potential of Live Rosin Cannabis Oil

Pharmagreen Biotech, Inc. (OTC PINKS: PHBI) has spotlighted the substantial revenue potential of its latest project, Live Rosin, a premium cannabis oil concentrate. During a special session on Creative Spaces, CEO Peter Wojcik detailed the company's advancements and strategies, emphasizing the product's purity, potency, and flavor profile achieved through a solventless extraction process. This method, coupled with the company's Standard Organic Non-Spray Cultivation Procedures (SONSCP), ensures high cannabinoid recovery rates and maintains the plant's natural properties.

The company's innovative farming and processing model aims to produce an average of 6,000 liters of Live Rosin per 100-acre farm per crop cycle, with 4 to 5 cycles annually. Given the current U.S. retail prices of $40 to $100 per gram, and even higher in Europe, Pharmagreen's revenue projections are ambitious. Estimates range from $19 million in the first year at $1 per gram to a staggering $635 million by the third year at $20 per gram.

To capitalize on these opportunities, Pharmagreen is pursuing distributors, joint ventures, and the acquisition of a cGMP-certified cannabis lab in Europe. This strategic approach is designed to secure a foothold in the lucrative EU market. However, the realization of these projections hinges on several critical milestones, including obtaining necessary licenses, permits, and funding.

CEO Peter Wojcik expressed optimism about the project's potential, stating, 'The revenue projections are indeed promising, and I am eager to bring them to fruition once the initial milestones are achieved.' The company's progress towards these objectives underscores its commitment to innovation and market expansion in the cannabis and psychedelic industries.